

6606

ADAM9 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H M R Mk	Sensitivity: Endogenous	MW (kDa): 100 pro-ADAM9-L, 80 ADAM9-L	Source/Isotype: Rabbit	UniProt ID: #Q13443	Entrez-Gene Id: 8754
Product Usage Information		Application Western Blotting Immunoprecipitatio	n		Dilution 1:1000 1:100	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		ADAM9 Antibody detects endogenous levels of total ADAM9 protein, unprocessed and active forms. The antibody does not recognize the carboxy terminally truncated short form of ADAM9. In some cell types, the antibody cross-reacts with a 50 kDa band of unknown origin.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the carboxy terminus of human ADAM9. Antibodies are purified using protein A and peptide affinity chromatography.				
Background		cell signaling and ac influencing cell adhe Conserved domains domain, a disintegri tail (1,2). The prodomain is th adhesion, at least in as its interaction wit ADAM9 is widely dis Research studies ha gastric cancer (7), ar	egrin and A Metallopro Ihesion by shedding ce esion to the extracellul- in ADAM family memb n domain, a cysteine-ri ought to aid in protein part, through binding h other signaling prote tributed and has been we shown that ADAM9 nd has been linked to in an alternatively spliced cell invasion (9).	ell surface proteins suc ar matrix (ECM), and b pers include a prodoma ich domain, an EGF-like folding. Disintegrin au to integrins. Phospho eins may influence intr shown to affect migra is overexpressed in provasion and metastasi	h as cytokines and y directly remodelir in, a zinc-depende e sequence, and a sond cysteine-rich doing a and extracellular tion in skin kerating ostate cancer (5), pos in small cell lung of the cytological in the cytologica	growth factors, by one the ECM. Int metalloprotease short cytoplasmic mains mediate plasmic tail as well signaling (1). Docytes (3,4). Cancer (8). Research
Background Ref	erences	 N. M. Hooper and U. Lendeckel The Netherlands: Springer, 2005 Schlöndorff, J. and Blobel, C.P. (1999) J Cell Sci 112 (Pt 21), 3603-17. Franzke, C.W. et al. (2002) EMBO J 21, 5026-35. Zigrino, P. et al. (2007) J Biol Chem 282, 30785-93. Fritzsche, F.R. et al. (2008) Eur Urol 54, 1097-106. Grützmann, R. et al. (2004) Br J Cancer 90, 1053-8. Carl-McGrath, S. et al. (2005) Int J Oncol 26, 17-24. Shintani, Y. et al. (2004) Cancer Res 64, 4190-6. Mazzocca, A. et al. (2005) Cancer Res 65, 4728-38. 				
Species Peactivit			determined by testing			

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4° C with gentle shaking, overnight.

Applications Key W: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key H: Human M: Mouse R: Rat Mk: Monkey

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.